Tag Archives: Hunter-Hopkins Center
Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021 AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading
Posted in News
Tagged ampligen, COVID-19, Dr Charles Lapp, Hunter-Hopkins Center, long Covid, long haulers, post-viral fatigue syndrome, Rintatolimod
Comments Off on Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
